Skip to main content
Clinical Trials/NCT05766553
NCT05766553
Recruiting
Not Applicable

Effects of Mindfulness Meditation in Virtual Reality on Craving and Smoking Cessation

Centre Hospitalier Henri Laborit3 sites in 1 country200 target enrollmentJune 15, 2023

Overview

Phase
Not Applicable
Intervention
Virtual reality pod
Conditions
Tobacco Use Disorder
Sponsor
Centre Hospitalier Henri Laborit
Enrollment
200
Locations
3
Primary Endpoint
Relapse at 3 months
Status
Recruiting
Last Updated
3 months ago

Overview

Brief Summary

Investigators seek to propose a non-drug therapeutic alternative, namely a mindfulness meditation protocol based on virtual reality training in order to induce progressive modifications of various indicators of craving.

The study hypothesis is that the practice of mindfulness meditation in a virtual reality environment reduces the craving induced by cues and stress and therefore ultimately smoking relapse.

The main objective of the protocol will be to demonstrate that mindfulness meditation can reduce long-term relapse (continuous cessation (> 30 days) of smoking cessation).

The participants will be randomized into two groups: the experimental group will perform six virtual reality sessions in a multisensory cabin at the rate of one session per week; the control group will be prescribed the gold standard treatment (nicotine patches and chewing gum).

Participants will be seen again at three and six months to assess whether or not there has been a smoking relapse.

Registry
clinicaltrials.gov
Start Date
June 15, 2023
End Date
December 15, 2026
Last Updated
3 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Any patient consuming 10 to 40 cigarettes per day
  • Woman or man aged 18 to 75 inclusive
  • Substance use disorder according to the DSM5 classification
  • Benefit from social security or benefit from it through a third party in accordance with French law on research involving the human person
  • Having signed the informed consent form after having received written information.

Exclusion Criteria

  • Disabling cognitive disorders
  • Patient under 18 or over 75 years old.
  • Patient with a psychological disorder or a psychiatric pathology requiring specialized follow-up
  • Patient with addiction to another product.
  • Cardiological pathologies that could compromise the participation of patients, detected by an ECG (only for patients who will be randomized in the experimental group).
  • Advanced pulmonary, renal, and hepatic diseases, or any unstable and serious medical conditions that could compromise the patient's participation in the study, subject to the judgment of the doctor
  • Pregnant or breastfeeding woman
  • Simultaneous participation in another trial
  • Employee of the investigator or of the clinical trial site
  • Patients protected by law

Arms & Interventions

Interventional Group

Patients in this arm will have 6 sessions of virtual reality in a pod (1 session per week). Patients will then have a visit at day 90 and day 180.

Intervention: Virtual reality pod

Control group

Patients in this arm will receive the gold standard of treatment for tobacco cessation (nicotine patches and chewing gum) from day 0 (inclusion visit) to day 90. Patients will then have a visit at day 90 and day 180.

Intervention: nicotine patches and chewing gum

Outcomes

Primary Outcomes

Relapse at 3 months

Time Frame: 3 months

Relapse of patients by declaring their consumption at 3 months.

Relapse at 6 months

Time Frame: 6 months

Relapse of patients by declaring their consumption at 6 months.

Study Sites (3)

Loading locations...

Similar Trials